Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT3 | P36888 | 5/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | CDK2 | P24941 | 4/20 | 0.47 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.47 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.46 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.46 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.46 |
| ▸ | KDR | P35968 | 3/20 | 0.45 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.43 |
| ▸ | AURKA | O14965 | 3/20 | 0.43 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.43 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.43 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.42 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4015690 | 1.00 | FLT3 (0.50) | FLT3MEN1KMT2ACDK2ALK | |
| SCHEMBL4168589 | 0.82 | FLT3 (0.46) | FLT3MEN1KMT2ACDK2ALK | |
| SCHEMBL4168596 | 0.82 | FLT3 (0.46) | FLT3MEN1KMT2ACDK2ALK | |
| SCHEMBL4013834 | 0.81 | MEN1 (0.60) | FLT3MEN1KMT2ACDK2ALK | |
| SCHEMBL4013829 | 0.81 | MEN1 (0.60) | FLT3MEN1KMT2ACDK2ALK | |
| SCHEMBL4014510 | 0.81 | ALK (0.57) | FLT3MEN1KMT2ACDK2ALK | |
| SCHEMBL4014512 | 0.81 | ALK (0.57) | FLT3MEN1KMT2ACDK2ALK | |
| SCHEMBL4019874 | 0.80 | FLT3 (0.49) | FLT3MEN1KMT2ACDK2ALK | |
| SCHEMBL4019883 | 0.80 | FLT3 (0.49) | FLT3MEN1KMT2ACDK2ALK | |
| SCHEMBL4014882 | 0.74 | FLT3 (0.57) | FLT3MEN1KMT2ACDK2ALK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009085040-A1 | PROTEIN KINASE INHIBITORS | DCB-USA LLC (US) | 2009-07-09 | — | — | WO | disclosed |
| US-20090163494-A1 | PROTEIN KINASE INHIBITORS | DEVELOPMENT CENTER FOR BIOTECHNOLOGY (TW) | 2009-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163494-A1 | PROTEIN KINASE INHIBITORS | BRAF, MAP3K20, SELENOI | FLT3 641/4885MEN1 893/4885KMT2A 1340/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.